Boston Scientific (NYSE: BSX) reported a robust second quarter, surpassing Wall Street expectations and prompting an upward revision of its full-year outlook. The company posted $797 million in net income, or 54¢ per share, on $5.06 billion in revenue—a 22.8% year-over-year increase. Adjusted EPS reached 75¢, beating forecasts by 2¢, while revenue outpaced the projected $4.89 billion.
Strong cardiovascular growth led the quarter, with a 26.8% increase, followed by MedSurg at 15.7%. Cardiology (29.3%), Urology (28.9%), and Peripheral Interventions (18.3%) also delivered standout performances. The company closed acquisitions of SoniVie, Bolt Medical, and Intera Oncology during the quarter, contributing to its broader strategy for innovation and portfolio expansion.
With continued operational efficiency and strategic investments, Boston Scientific now expects full-year adjusted EPS between $2.95 and $2.99, up from $2.87–$2.94. Revenue growth guidance also increased, now projected at 18% to 19%, compared to the previous 15% to 17%.
Follow MEDWIRE.AI for more updates on medtech earnings and market movements.
